A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects

NCT ID: NCT04143477

Last Updated: 2024-10-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-05
• Study Completion Date: 2020-12-21

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of ASP015K after single-dose and multiple-dose administration in healthy Chinese participants.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Peficitinib 50 mg

Participants will receive a single dose of 50 milligrams (mg) under fasted condition Day 1, followed by multiple doses of 50 mg under fed condition once daily in the morning from Day 8 till Day 13.

Group Type: EXPERIMENTAL

peficitinib

Intervention Type: DRUG

Oral

Peficitinib 100 mg

Participants will receive a single dose of 100 mg under fasted condition Day 1, followed by multiple doses of 100 mg under fed condition once daily in the morning from Day 8 till Day 13.

Group Type: EXPERIMENTAL

peficitinib

Intervention Type: DRUG

Oral

Peficitinib 150 mg

Participants will receive a single dose of 150 mg under fasted condition Day 1, followed by multiple doses of 150 mg under fed condition once daily in the morning from Day 8 till Day 13.

Group Type: EXPERIMENTAL

peficitinib

Intervention Type: DRUG

Oral

Interventions

peficitinib

Oral

Intervention Type: DRUG

Other Intervention Names

ASP015K

Eligibility Criteria

Inclusion Criteria

• Normal Body Mass index (BMI) and weight: BMI[= weight kg/(height m)^2] > 19 kg/m^2 and ≤ 24 kg/m^2, the weight is no less than 50 kg for male and 45 kg for female at screening.
• Female subject must either: Be of non-childbearing potential, postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile. Or, if of childbearing potential: agree not to try to become pregnant during the study and for 60 days after the final study drug administration, must have a negative pregnancy at Screening and Day -1, and if heterosexually active, agree to consistently use 1 form of highly effective birth control starting at Screening and throughout the study period, and for 60 days after the final study drug administration.
• Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 60 days after the final study drug administration.
• Female subject must not donate ova starting at Screening and throughout the study period, and for 60 days after the final study drug administration.
• Male subject and female spouse/partners who are of childbearing potential must be using 1 form of highly effective birth control starting at Screening and throughout the study period, and for 90 days after the final study drug administration.
• Male subject must not donate sperm starting at Screening and throughout the study period, and for 90 days after the final study drug administration.
• Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria

• Female subject who has been pregnant within 6 months prior to screening or breast feeding within 3 months prior to screening.
• Subject has a known or suspected hypersensitivity to ASP015K, or any components of the formulation used.
• Subject has any of the liver chemistry tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT] and total bilirubin [TBL]) above the upper limit of normal on Day -1. In such a case, the assessment may be repeated once.
• Subjects who meet any of the following criterion for laboratory tests on Day -1. Normal ranges of each test specified at the study site or test/assay organization will be used as the normal ranges in this study. In such a case, the assessment may be repeated once.

• Hematology: a deviation of +20% from the upper limit or -20% from the lower limit of the normal range, and clinically significant.
• Blood biochemistry: a deviation from the normal range regarding serum creatinine, serum electrolytes (Na, K, and Cl), or fasting blood glucose; a deviation of +20% from the upper limit or -20% from the lower limit of the normal range regarding laboratory test items other than above, and clinically significant. However, the lower limit of the normal range will not be established for lactate dehydrogenase (LD), creatinine kinase (CK), total cholesterol, triglyceride, urea, serum creatinine, and uric acid, whose deviation from the lower limit is considered not clinically significant.
• Urinalysis: a deviation from the normal range of each urinalysis test item.
• Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, respiratory,pulmonary, neurologic, cerebrovascular, lymphatic, dermatologic, psychiatric, renal, and/or other major disease or malignancy.
• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to Day -1.
• Subject has any clinically significant abnormality in the physical examination, 12-lead electrocardiogram (ECG) and protocol defined clinical laboratory tests at Screening or Day -1.
• Subject has a pulse rate < 45 or > 100 bpm; systolic blood pressure (SBP) > 140 mmHg; diastolic blood pressure (DBP) > 90 mmHg (measurements taken after subject has been resting in sit position for 5 min; pulse will be measured automatically) at screening or on Day -1. If the pulse rate or blood pressure exceeds the limits above, 1 additional test can be taken.
• Subjects with abnormal body temperature, defined as axillary temperature >37.3 ºC or <35.0 ºC at Screening or Day -1.
• Subject has a corrected QT interval (QTcF) of > 430 ms (for males) and > 450 ms (for females) at screen or on Day -1(at screen and on Day-1, will be performed). If the QTcF exceeds the limits above on Day-1, 1 additional ECG test can be taken.
• Subject has any history or evidence of congenital short QT syndrome(defined as QTc < 330 ms).
• Subject has any history of gastrointestinal resection (excepted appendectomy)..
• Subject has developed upper gastrointestinal symptoms within 1 week prior to Day -1.
• Subject applies to any of the following concerns with regard to tuberculosis.

• History of active tuberculosis
• Abnormalities detected in a chest X-ray test at Screening
• Contact with infectious tuberculous patients
• T-spot or Quantiferon Gold test show tuberculosisinfection positive.
• Subject applies to any of the following concerns with regard to infection other than tuberculosis.

• Complication or history of severe herpes zoster or herpes zoster disseminated.
• At least twice of relapse of localized herpes zoster
• Inpatient hospital care for severe infectious diseases within 90 days prior to Day -1
• Treatment with intravenous antibiotics within 90 days prior to Day -1 (prophylactic antibiotics are not applicable).
• Other than above, with a high risk of developing infectious disease (subjects with urethral catheterisation etc.).
• Subject has vaccination of live vaccines or live attenuated vaccines within 56 days prior to Day -1 (inactivated vaccines such as influenza vaccine and pneumococcal vaccines are not applicable.).
• Subject has used any prescribed or nonprescribed drugs (including vitamins or natural and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug administration.
• Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
• Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) (> 14units of alcohol for female subjects) within 3 months prior to admission to the clinical unit or the subject tests positive for alcohol or drugs of abuse at Screening or Day -1 (amphetamines,barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).
• Subject has used any drugs of abuse within 3 months prior to admission to the clinical unit.
• Subject has had significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to Day -1.
• Subject has a positive serology test for hepatitis B surface antigen (HBsAg), antihepatitis A virus (immunodeficiency virus [Ig]M), anti-hepatitis C virus, anti-hepatitis B core or antihuman immunodeficiency virus (HIV) at Screening.
• Subject has participated in any clinical study or has been treated with any investigational drugs within 3 moths prior to screening.
• Subject has any condition which makes the subject unsuitable for study participation.
• Subject is an employee of the Astellas Group, Clinical Research Organization (CRO) or the clinical unit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Astellas Pharma China, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Moniter, Senior Manager

Role: STUDY_DIRECTOR

Astellas Pharma China, Inc.

Locations

Site CN86001

Beijing, , China

Countries

China

References

Gao X, He X, Oshima H, Miyatake D, Otsuka Y, Kato K, Cai C, Wojtkowski T, Song N, Kaneko Y, Shi A. Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects. Drug Des Devel Ther. 2022 May 9;16:1365-1381. doi: 10.2147/DDDT.S359501. eCollection 2022.

Reference Type: DERIVED

PMID: 35586186 (View on PubMed)

Other Identifiers

015K-CL-CNA1

Identifier Type: -

Identifier Source: org_study_id